表皮生长因子受体酪氨酸激酶抑制剂联合化疗治疗晚期非小细胞肺癌的有效性及安全性  

Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined with Chemotherapy in Treatment of Advanced Advanced Non-small Cell Lung Cancer

作　　者：曹凤[1] 王德林[1] 曹玉娟[1] 李兆鑫[2] 曹邦伟[2] 颜博[3] 

机构地区：[1]北京大学首钢医院肿瘤科,北京100041 [2]首都医科大学附属北京友谊医院肿瘤科,北京100050 [3]德克萨斯大学圣安东尼奥健康科学中心微生物与免疫学系

出　　处：《中国医院用药评价与分析》2016年第9期1153-1155,共3页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家自然科学基金资助(No.81272615)

摘　　要：目的:观察表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)与化疗联合治疗晚期非小细胞肺癌的疗效,并对其预后及安全性进行探讨。方法:选取2013年2月—2014年11月收治的晚期非小细胞肺癌患者48例,按随机数字表法平均分为研究组和对照组,对照组患者采用单纯化疗,研究组患者在单纯化疗的基础上联合使用EGFR-TKI,治疗结束后评估2组患者的治疗效果与安全性。结果:2组患者有效率和总生存时间的差异无统计学意义(P>0.05);研究组患者的疾病控制率和无疾病进展时间均明显高于对照组,差异均有统计学意义(P<0.05);2组患者均出现一定级别的不良反应,但不良反应发生率较低,且2组间的差异无统计学意义(P>0.05)。结论:相对于单纯化疗,使用EGFR-TKI联合化疗治疗晚期非小细胞肺癌,更有利于疾病的控制、延缓肿瘤进展时间,且安全性较好。OBJECTIVE： To observe the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor（ EGFR-TKI） combined with chemotherapy in treatment of advanced advanced non-small cell lung cancer（ NSCLC）,and to probe into the prognosis and safety. METHODS： 48 patients with NSCLC admitted from Feb. 2013 to Nov.2014 were selected to be divided into observation group and control group via the random number table. The control group were treated with simple chemotherapy,while the observation group were additionally given EGFR-TKI based on the control group. The treatment effects and safety of two groups were evaluated after treatment. RESULTS： There was no statistical significance between two groups in effective rate and overall survival time（ P 〉0. 05）. The disease control rate and progression-free survival of observation group were significantly higher than those of control group,with statistically significant difference（ P〈 0. 05）. There were adverse drug reactions in both groups,yet the incidence was relatively low, and the difference was not significant（ P 〉0. 05）. CONCLUSIONS： Compared with simple chemotherapy,EGFR-TKI combined with chemotherapy in treatment of NSCLC can effective control the diseases and delay the tumor progression of time with high safety.

关 键 词：EGFR-TKI 非小细胞肺癌 化疗 

分 类 号：R979.1[医药卫生—药品]